
Moderna
Financials
Market Cap
$49.13B5Y beta
1.69EPS (TTM)
$11.57Free Float
346.94MP/E ratio (TTM)
11.14Revenue (TTM)
$15.06BEBITDA (TTM)
$5.17BFree Cashflow (TTM)
$612.00MPricing
Open
n/aClose
n/aAnalyst Ratings
The price target is $218.80 and the stock is covered by 21 analysts.
Buy
10
Hold
10
Sell
1
Information
Moderna, Inc. is a biotechnology company. The Company is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The Company's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). It has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.